Cite
HARVARD Citation
Luke, J. et al. (n.d.). 367 A phase 1/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with atezolizumab in patients with advanced solid tumors. Journal for immunotherapy of cancer. p. A224. [Online].